Analysts See $-0.01 EPS for DiaMedica Therapeutics Inc. (DMA)

November 10, 2018 - By Adrian Mccoy

DiaMedica Therapeutics Inc. (CVE:DMA) Logo

Analysts expect DiaMedica Therapeutics Inc. (CVE:DMA) to report $-0.01 EPS on November, 26.They anticipate $0.00 EPS change or 0.00 % from last quarter’s $-0.01 EPS. After having $-0.03 EPS previously, DiaMedica Therapeutics Inc.’s analysts see -66.67 % EPS growth. The stock decreased 4.55% or $0.02 during the last trading session, reaching $0.42. About 96,316 shares traded. DiaMedica Therapeutics Inc. (CVE:DMA) has 0.00% since November 11, 2017 and is . It has underperformed by 15.62% the S&P500.

DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of novel recombinant proteins and monoclonal antibodies. The company has market cap of $65.85 million. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein with a focus on acute vascular diseases, such as acute ischemic stroke and kidney injury indications. It currently has negative earnings. It also develops DMDx, a companion diagnostic in vitro assay for kidney diseases.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News